A Phase 2 Study to Evaluate the Safety, PD, PK, and Clinical Activity of ADX-097 in Participants With IgAN, LN or C3G

NCT06419205 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped study closed prior to enrolling any patients.

Conditions

IgA Nephropathy
Lupus Nephritis (LN)
C3 (Complement Component 3) Glomerulopathy

Interventions

DRUG: ADX-097

Sponsor

Q32 Bio Inc.